Efficacy and safety of deep transcranial magnetic stimulation for major depression

A prospective multicenter randomized controlled trial

Yechiel Levkovitz, Moshe Isserles, Frank Padberg, Sarah H. Lisanby, Alexander Bystritsky, Guohua Xia, Aron Tendler, Zafiris J. Daskalakis, Jaron L. Winston, Pinhas Dannon, Hisham M. Hafez, Irving M. Reti, Oscar G. Morales, Thomas E. Schlaepfer, Eric Hollander, Joshua A. Berman, Mustafa M. Husain, Uzi Sofer, Ahava Stein, Shmulik Adler & 5 others Lisa Deutsch, Frederic Deutsch, Yiftach Roth, Mark S. George, Abraham Zangen

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Major depressive disorder (MDD) is a prevalent and disabling condition, and many patients do not respond to available treatments. Deep transcranial magnetic stimulation (dTMS) is a new technology allowing non-surgical stimulation of relatively deep brain areas. This is the first double-blind randomized controlled multicenter study evaluating the efficacy and safety of dTMS in MDD. We recruited 212 MDD outpatients, aged 22-68 years, who had either failed one to four antidepressant trials or not tolerated at least two antidepressant treatments during the current episode. They were randomly assigned to monotherapy with active or sham dTMS. Twenty sessions of dTMS (18 Hz over the prefrontal cortex) were applied during 4 weeks acutely, and then biweekly for 12 weeks. Primary and secondary efficacy endpoints were the change in the Hamilton Depression Rating Scale (HDRS-21) score and response/remission rates at week 5, respectively. dTMS induced a 6.39 point improvement in HDRS-21 scores, while a 3.28 point improvement was observed in the sham group (p=0.008), resulting in a 0.76 effect size. Response and remission rates were higher in the dTMS than in the sham group (response: 38.4 vs. 21.4%, p=0.013; remission: 32.6 vs. 14.6%, p=0.005). These differences between active and sham treatment were stable during the 12-week maintenance phase. dTMS was associated with few and minor side effects apart from one seizure in a patient where a protocol violation occurred. These results suggest that dTMS constitutes a novel intervention in MDD, which is efficacious and safe in patients not responding to antidepressant medications, and whose effect remains stable over 3 months of maintenance treatment.

Original languageEnglish (US)
Pages (from-to)64-73
Number of pages10
JournalWorld Psychiatry
Volume14
Issue number1
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Transcranial Magnetic Stimulation
Randomized Controlled Trials
Depression
Safety
Major Depressive Disorder
Antidepressive Agents
Deep Brain Stimulation
Prefrontal Cortex
Multicenter Studies
Seizures
Outpatients
Therapeutics
Placebos
Maintenance
Technology

Keywords

  • Deep transcranial magnetic stimulation
  • maintenance treatment
  • major depressive disorder
  • remission
  • response
  • treatment resistance

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Phychiatric Mental Health

Cite this

Levkovitz, Y., Isserles, M., Padberg, F., Lisanby, S. H., Bystritsky, A., Xia, G., ... Zangen, A. (2015). Efficacy and safety of deep transcranial magnetic stimulation for major depression: A prospective multicenter randomized controlled trial. World Psychiatry, 14(1), 64-73. https://doi.org/10.1002/wps.20199

Efficacy and safety of deep transcranial magnetic stimulation for major depression : A prospective multicenter randomized controlled trial. / Levkovitz, Yechiel; Isserles, Moshe; Padberg, Frank; Lisanby, Sarah H.; Bystritsky, Alexander; Xia, Guohua; Tendler, Aron; Daskalakis, Zafiris J.; Winston, Jaron L.; Dannon, Pinhas; Hafez, Hisham M.; Reti, Irving M.; Morales, Oscar G.; Schlaepfer, Thomas E.; Hollander, Eric; Berman, Joshua A.; Husain, Mustafa M.; Sofer, Uzi; Stein, Ahava; Adler, Shmulik; Deutsch, Lisa; Deutsch, Frederic; Roth, Yiftach; George, Mark S.; Zangen, Abraham.

In: World Psychiatry, Vol. 14, No. 1, 01.02.2015, p. 64-73.

Research output: Contribution to journalArticle

Levkovitz, Y, Isserles, M, Padberg, F, Lisanby, SH, Bystritsky, A, Xia, G, Tendler, A, Daskalakis, ZJ, Winston, JL, Dannon, P, Hafez, HM, Reti, IM, Morales, OG, Schlaepfer, TE, Hollander, E, Berman, JA, Husain, MM, Sofer, U, Stein, A, Adler, S, Deutsch, L, Deutsch, F, Roth, Y, George, MS & Zangen, A 2015, 'Efficacy and safety of deep transcranial magnetic stimulation for major depression: A prospective multicenter randomized controlled trial', World Psychiatry, vol. 14, no. 1, pp. 64-73. https://doi.org/10.1002/wps.20199
Levkovitz, Yechiel ; Isserles, Moshe ; Padberg, Frank ; Lisanby, Sarah H. ; Bystritsky, Alexander ; Xia, Guohua ; Tendler, Aron ; Daskalakis, Zafiris J. ; Winston, Jaron L. ; Dannon, Pinhas ; Hafez, Hisham M. ; Reti, Irving M. ; Morales, Oscar G. ; Schlaepfer, Thomas E. ; Hollander, Eric ; Berman, Joshua A. ; Husain, Mustafa M. ; Sofer, Uzi ; Stein, Ahava ; Adler, Shmulik ; Deutsch, Lisa ; Deutsch, Frederic ; Roth, Yiftach ; George, Mark S. ; Zangen, Abraham. / Efficacy and safety of deep transcranial magnetic stimulation for major depression : A prospective multicenter randomized controlled trial. In: World Psychiatry. 2015 ; Vol. 14, No. 1. pp. 64-73.
@article{a16f176c748f4d3ab02a4c2e2b169060,
title = "Efficacy and safety of deep transcranial magnetic stimulation for major depression: A prospective multicenter randomized controlled trial",
abstract = "Major depressive disorder (MDD) is a prevalent and disabling condition, and many patients do not respond to available treatments. Deep transcranial magnetic stimulation (dTMS) is a new technology allowing non-surgical stimulation of relatively deep brain areas. This is the first double-blind randomized controlled multicenter study evaluating the efficacy and safety of dTMS in MDD. We recruited 212 MDD outpatients, aged 22-68 years, who had either failed one to four antidepressant trials or not tolerated at least two antidepressant treatments during the current episode. They were randomly assigned to monotherapy with active or sham dTMS. Twenty sessions of dTMS (18 Hz over the prefrontal cortex) were applied during 4 weeks acutely, and then biweekly for 12 weeks. Primary and secondary efficacy endpoints were the change in the Hamilton Depression Rating Scale (HDRS-21) score and response/remission rates at week 5, respectively. dTMS induced a 6.39 point improvement in HDRS-21 scores, while a 3.28 point improvement was observed in the sham group (p=0.008), resulting in a 0.76 effect size. Response and remission rates were higher in the dTMS than in the sham group (response: 38.4 vs. 21.4{\%}, p=0.013; remission: 32.6 vs. 14.6{\%}, p=0.005). These differences between active and sham treatment were stable during the 12-week maintenance phase. dTMS was associated with few and minor side effects apart from one seizure in a patient where a protocol violation occurred. These results suggest that dTMS constitutes a novel intervention in MDD, which is efficacious and safe in patients not responding to antidepressant medications, and whose effect remains stable over 3 months of maintenance treatment.",
keywords = "Deep transcranial magnetic stimulation, maintenance treatment, major depressive disorder, remission, response, treatment resistance",
author = "Yechiel Levkovitz and Moshe Isserles and Frank Padberg and Lisanby, {Sarah H.} and Alexander Bystritsky and Guohua Xia and Aron Tendler and Daskalakis, {Zafiris J.} and Winston, {Jaron L.} and Pinhas Dannon and Hafez, {Hisham M.} and Reti, {Irving M.} and Morales, {Oscar G.} and Schlaepfer, {Thomas E.} and Eric Hollander and Berman, {Joshua A.} and Husain, {Mustafa M.} and Uzi Sofer and Ahava Stein and Shmulik Adler and Lisa Deutsch and Frederic Deutsch and Yiftach Roth and George, {Mark S.} and Abraham Zangen",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/wps.20199",
language = "English (US)",
volume = "14",
pages = "64--73",
journal = "World Psychiatry",
issn = "1723-8617",
publisher = "Masson SpA",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of deep transcranial magnetic stimulation for major depression

T2 - A prospective multicenter randomized controlled trial

AU - Levkovitz, Yechiel

AU - Isserles, Moshe

AU - Padberg, Frank

AU - Lisanby, Sarah H.

AU - Bystritsky, Alexander

AU - Xia, Guohua

AU - Tendler, Aron

AU - Daskalakis, Zafiris J.

AU - Winston, Jaron L.

AU - Dannon, Pinhas

AU - Hafez, Hisham M.

AU - Reti, Irving M.

AU - Morales, Oscar G.

AU - Schlaepfer, Thomas E.

AU - Hollander, Eric

AU - Berman, Joshua A.

AU - Husain, Mustafa M.

AU - Sofer, Uzi

AU - Stein, Ahava

AU - Adler, Shmulik

AU - Deutsch, Lisa

AU - Deutsch, Frederic

AU - Roth, Yiftach

AU - George, Mark S.

AU - Zangen, Abraham

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Major depressive disorder (MDD) is a prevalent and disabling condition, and many patients do not respond to available treatments. Deep transcranial magnetic stimulation (dTMS) is a new technology allowing non-surgical stimulation of relatively deep brain areas. This is the first double-blind randomized controlled multicenter study evaluating the efficacy and safety of dTMS in MDD. We recruited 212 MDD outpatients, aged 22-68 years, who had either failed one to four antidepressant trials or not tolerated at least two antidepressant treatments during the current episode. They were randomly assigned to monotherapy with active or sham dTMS. Twenty sessions of dTMS (18 Hz over the prefrontal cortex) were applied during 4 weeks acutely, and then biweekly for 12 weeks. Primary and secondary efficacy endpoints were the change in the Hamilton Depression Rating Scale (HDRS-21) score and response/remission rates at week 5, respectively. dTMS induced a 6.39 point improvement in HDRS-21 scores, while a 3.28 point improvement was observed in the sham group (p=0.008), resulting in a 0.76 effect size. Response and remission rates were higher in the dTMS than in the sham group (response: 38.4 vs. 21.4%, p=0.013; remission: 32.6 vs. 14.6%, p=0.005). These differences between active and sham treatment were stable during the 12-week maintenance phase. dTMS was associated with few and minor side effects apart from one seizure in a patient where a protocol violation occurred. These results suggest that dTMS constitutes a novel intervention in MDD, which is efficacious and safe in patients not responding to antidepressant medications, and whose effect remains stable over 3 months of maintenance treatment.

AB - Major depressive disorder (MDD) is a prevalent and disabling condition, and many patients do not respond to available treatments. Deep transcranial magnetic stimulation (dTMS) is a new technology allowing non-surgical stimulation of relatively deep brain areas. This is the first double-blind randomized controlled multicenter study evaluating the efficacy and safety of dTMS in MDD. We recruited 212 MDD outpatients, aged 22-68 years, who had either failed one to four antidepressant trials or not tolerated at least two antidepressant treatments during the current episode. They were randomly assigned to monotherapy with active or sham dTMS. Twenty sessions of dTMS (18 Hz over the prefrontal cortex) were applied during 4 weeks acutely, and then biweekly for 12 weeks. Primary and secondary efficacy endpoints were the change in the Hamilton Depression Rating Scale (HDRS-21) score and response/remission rates at week 5, respectively. dTMS induced a 6.39 point improvement in HDRS-21 scores, while a 3.28 point improvement was observed in the sham group (p=0.008), resulting in a 0.76 effect size. Response and remission rates were higher in the dTMS than in the sham group (response: 38.4 vs. 21.4%, p=0.013; remission: 32.6 vs. 14.6%, p=0.005). These differences between active and sham treatment were stable during the 12-week maintenance phase. dTMS was associated with few and minor side effects apart from one seizure in a patient where a protocol violation occurred. These results suggest that dTMS constitutes a novel intervention in MDD, which is efficacious and safe in patients not responding to antidepressant medications, and whose effect remains stable over 3 months of maintenance treatment.

KW - Deep transcranial magnetic stimulation

KW - maintenance treatment

KW - major depressive disorder

KW - remission

KW - response

KW - treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=84922948341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922948341&partnerID=8YFLogxK

U2 - 10.1002/wps.20199

DO - 10.1002/wps.20199

M3 - Article

VL - 14

SP - 64

EP - 73

JO - World Psychiatry

JF - World Psychiatry

SN - 1723-8617

IS - 1

ER -